Tumor supernatant from myeloid malignancies inhibits T-cell apoptosis and cell cycle entry independently.
Milojkovic
D
D
Buggins
A G S
AG
Devereux
S
S
Thomas
N S B
NS
Mufti
G J
GJ
D017209:Apoptosis / Q000187:drug effects* / Q000276:immunology; D002453:Cell Cycle / Q000187:drug effects; D002478:Cells, Cultured; D018920:Coculture Techniques; D017077:Culture Media, Conditioned / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D007376:Interleukin-2 / Q000037:antagonists & inhibitors; D007621:Karyotyping; D007951:Leukemia, Myeloid / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D016271:Proto-Oncogene Proteins c-myc / Q000037:antagonists & inhibitors; D016160:Retinoblastoma Protein / Q000037:antagonists & inhibitors; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D019139:Tumor Escape / Q000276:immunology
D017077:Culture Media, Conditioned; D007376:Interleukin-2; D016271:Proto-Oncogene Proteins c-myc; D016160:Retinoblastoma Protein